- Clinical Trials
- April 2024
- 50 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- January 2024
- 250 Pages
Global
From €7673EUR$7,950USD£6,582GBP
- Report
- January 2022
- 150 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Drug Pipelines
- April 2021
- 78 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Report
- October 2018
- 17 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- October 2018
- 15 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- October 2018
- 20 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£414GBP
- Report
- January 2019
- 35 Pages
Global
From €965EUR$1,000USD£828GBP
Remodulin is a brand of cardiovascular drugs used to treat pulmonary arterial hypertension (PAH). It is a vasodilator, meaning it relaxes the blood vessels, allowing for increased blood flow and improved oxygen delivery to the lungs. Remodulin is administered through an intravenous infusion, and is available in both a short-acting and a long-acting form. The drug is used to reduce symptoms of PAH, such as shortness of breath, fatigue, and chest pain. It can also help improve exercise capacity and quality of life.
Remodulin is a relatively new drug, having been approved by the US Food and Drug Administration in 2002. It is currently marketed by United Therapeutics Corporation, and is available in the United States, Canada, and Europe. Other companies involved in the market include Actelion Pharmaceuticals, Bayer, and GlaxoSmithKline. Show Less Read more
